Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has been banging the drum at the 2018 MDA Clinical Conference in Arlington, Virginia, about its PhaseOut DMD clinical trial.
Summit stressed the scientific rigour of PhaseOut DMD, a Phase 2 open-label trial of the company's utrophin modulator, ezutromid, in patients with Duchenne muscular dystrophy (DMD).
READ: Summit Therapeutics shares jump on 'exciting' interim results of ezutromid study
Through this study, Summit is compiling a deep dataset for each patient in the trial, which includes the analysis of several thousand muscle fibres per biopsy sample.
As part of this effort, steps are being taken to remove human bias through the automated reading of biopsy and modified Rankin scale (MRS) measurements at central sites.
"Since DMD is a muscle-wasting disorder, it is critical for us to have high quality data from objective muscle health measurements as we assess ezutromid's activity.
As the collection of muscle biopsy and MRS measurements are a major intervention for patients in clinical trials, it means it is crucial this is done in a robust and reliable way," said Dr David Roblin, the chief medical officer and president of research & development at Summit.
READ: Summit Therapeutics expands enrolment in Phase 2 PhaseOut DMD trial
"Our data collection and analysis methods used in PhaseOut DMD helped yield a high-quality dataset from all evaluable boys in the trial after 24-weeks of treatment. We are grateful to all the boys in the trial and excited about the interim findings that showed compelling signs of ezutromid activity," Dr Roblin said.